Murray 1997
| Methods | RCT: enrolled:445 evaluated: 429 | |
| Participants | Inclusion: 1. Proof of underlying primary 2. Measureable brain lesion(s) on CT/MRI 3. KPS ≥ 70 4. NFC 1 or 2 Exclusion: 1. Primary site hematopoeitc origin 2. Metastatic lymphoma involving meninges | |
| Interventions | 5440 cGy/34 fr (BID over 17 days) versus 3000 cGy/10 fr (over 10 days) | |
| Outcomes | 1. Survival (2. Acute toxicity) | |
| Notes | QS = 2 | |